FK‐506–A Novel Immunosuppressant

Annals of the New York Academy of Sciences

Volumn 685, Issue 1, 1993, Pages 22-36

  PARSONS, WILLIAM H ^a   SIGAL, NOLAN H ^a   WYVRATT, MATTHEW J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CALCINEURIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; L 685818; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTHRITIS; ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CONFERENCE PAPER; DIABETES MELLITUS; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RAT; SKIN DISEASE; SPECIES DIFFERENCE; STREPTOMYCES; T LYMPHOCYTE; TOXICITY;

ANIMAL; AUTOIMMUNE DISEASES; CALCINEURIN; CALMODULIN-BINDING PROTEINS; CARRIER PROTEINS; CYCLOSPORINE; GRAFT REJECTION; HUMAN; LYMPHOCYTE ACTIVATION; MOLECULAR CONFORMATION; PHOSPHOPROTEIN PHOSPHATASE; POLYENES; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

CANIS FAMILIARIS; STREPTOMYCES;

EID: 0027248887     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1993.tb35847.x     Document Type: Article

References (51)

1. Biological effects of cyclosporin A: A new antilymphocyte agent
2. Pharmacology of cyclosporine (Sandimmune) IV. Pharmacological properties in vivo
3. The effect of cyclosporine on the use of hospital resources for kidney transplantation
4. Cyclosporin A
5. FK‐506, A novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physico‐chemical and biological characteristics. 1987
6. FK‐506, A novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK‐506 in vitro
7. Pharmacokinetic study of FK‐506 in the rat
8. Synergistic interactions of cyclosporin and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
9. Cyclosporin in the treatment of Rheumatoid arthritis
10. Low dose cyclosporine A in psoriatic arthritis: Relation between soluble interleukin 2 receptors and response to therapy
11. Trial of cyclosporin in corticosteroid‐dependent chronic severe arthritis
12. Cyclosporin‐induced remission of IDDM after early intervention
13. The efficacy of cyclosporine in the treatment of Crohn's perianal and fistulous disease
14. Cyclosporine in the treatment of severe refractory ulcerative colitis
15. Low‐dose cyclosporin therapy of ocular inflammation: Preliminary report of a long‐term followup study
16. The usefulness of cyclosporin (Sandimmune) in the treatment of Beçer's syndrome: Preliminary results of an open study
17. Local cyclosporin A treatment in infiltrative endocrine ophthmopathy
18. Topical cyclosporin A in the treatment of external immunologically mediated ophthalmological diseases
19. Cyclosporin (Sandimmune) in chronic endogenous uveitis
20. FK‐506 in the management of transplant‐related nephrotic syndrome and steroid resistant nephrotic syndrome
21. Cyclosporin for severe idiopathic membranous nephropathy
22. Combined cyclosporin A/steroid treatment for SLE patients
23. Consensus conference on cyclosporin A for psoriasis
24. Tacrolimus (FK‐506)–A new therapeutic agent for severe recalcitrant psoriasis
25. Double‐blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
26. The immunosup‐pressant FK‐506 selectively inhibits expression of early T cell activation genes
27. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promotor
28. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK‐506 and rapamycin
29. The immunosuppressive macrolides FK‐506 and rapamycin act as reciprocal antagonists in murine T cells
30. A cytosolic binding protein for the immunosuppressant FK‐506 has peptidyl‐prolyl isomerase activity but is distinct from cyclophilin
31. Rapamycin and FK‐506 binding proteins (Immunophilins)
32. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK‐506 or rapamycin
33. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclopsorin A?
34. Calcineurin is a common target of cyclophilin‐cyclosporin A and FKBP‐FK‐506 complexes
35. The immunosuppressive and toxic effects of FK‐506 are mechanistically related: Pharmacology of a novel antagonist of FK‐506 and rapamycin
36. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK‐506 and cyclosporin A
37. FK‐506– and CsA‐sensitive activation of the interleukin‐2 promoter by calcineurin
38. Identification of calcineurin as a key signalling enzyme in lymphocyte‐T activation
39. Atomic structure of FKBP‐FK‐506, an immunophilin‐immunosuppressant complex
40. FK‐506–binding protein: Three‐dimensional structure of the complex with the antagonist L‐685,818
41. Solution structure of the major binding protein for the immunosuppressant FK‐506
42. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin
43. Solution structure of FK‐506 from nuclear magnetic resonance and molecular dynamics
44. Structure of a new macrocyclic antibiotic
45. Charged surface residues of FKBP12 participate in formation of the FKBP12–FK‐506–calcineurin complex
46. Critical trial of FK‐506 immunosuppression in adult cardiac transplantation
47. Studies of the effects of FK‐506 on renal allografting in the beagle dog
48. FK‐506–induced nephrotoxicity in rats